Eiry Roberts - 08 Nov 2024 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Medical Officer
Issuer ticker: NBIX
Reported as of: 08 Nov 2024
Net transaction value: +$599,873
SEC form: 4
Accepted by SEC: 12 Nov 2024, 17:58:47 UTC
Prior SEC filing: 07 Jun 2024
Next SEC filing: 19 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Eiry Roberts filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 12 Nov 2024.

Key facts

This page summarizes Eiry Roberts's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
8 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 12 Nov 2024, 17:58.

Change

Previous filing in this sequence was filed on 07 Jun 2024.
Current net transaction value: +$599,873.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Options Exercise

Transaction value: $399,943
Shares: +5,140
Change %: +22%
Price: $77.81
Shares after: 28,856
Date: 08 Nov 2024
Ownership: Direct
Footnotes: F1

NBIX transaction

Common Stock

Options Exercise

Transaction value: $99,935
Shares: +1,233
Change %: +4.3%
Price: $81.05
Shares after: 30,089
Date: 08 Nov 2024
Ownership: Direct
Footnotes: F1

NBIX transaction

Common Stock

Options Exercise

Transaction value: $99,916
Shares: +971
Change %: +3.2%
Price: $102.90
Shares after: 31,060
Date: 08 Nov 2024
Ownership: Direct
Footnotes: F1

NBIX transaction

Common Stock

Options Exercise

Transaction value: $79.02
Shares: +1
Change %: +0%
Price: $79.02
Shares after: 31,061
Date: 08 Nov 2024
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBIX transaction Derivative

Incentive Stock Option

Options Exercise

Transaction value: $0
Shares: -5,140
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Nov 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,140
Exercise price: $77.81
Footnotes: F3

NBIX transaction Derivative

Incentive Stock Option

Options Exercise

Transaction value: $0
Shares: -1,233
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Nov 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,233
Exercise price: $81.05
Footnotes: F4

NBIX transaction Derivative

Incentive Stock Option

Options Exercise

Transaction value: $0
Shares: -971
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Nov 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 971
Exercise price: $102.90
Footnotes: F5

NBIX transaction Derivative

Incentive Stock Option

Options Exercise

Transaction value: $0
Shares: -1
Change %: -0.08%
Price: $0.000000
Shares after: 1,265
Date: 08 Nov 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1
Exercise price: $79.02
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.

Footnote F2

29,876 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

Footnote F3

Represents option of which 1/4th of the shares underlying the option became vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.

Footnote F4

Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.

Footnote F5

Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.

Footnote F6

Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.